Assessing Arcutis Biotherapeutics After 99% YTD Surge and Mixed Valuation Signals [Yahoo! Finance]
Arcutis Biotherapeutics, Inc. - Common stock (ARQT)
Company Research
Source: Yahoo! Finance
The stock has been volatile lately, slipping about 7.0% over the last week, but it is still up 16.1% over 30 days, 99.3% year to date and 128.7% over the past year, which hints at shifting expectations and risk appetite. Those moves have come as investors focus on Arcutis Biotherapeutics' progress in dermatology, including regulatory milestones and an expanding commercial rollout that could reshape its long term revenue profile. At the same time, sentiment has been swinging as the market weighs execution risks against the potential for its lead treatments to capture meaningful share in crowded therapeutic areas. Against that backdrop, our valuation checks suggest Arcutis Biotherapeutics scores on undervaluation, which means it looks inexpensive on some metrics but not others. Next, we will break down what different valuation approaches are saying about the stock today, and then finish with a more holistic way to think about what Arcutis Biotherapeutics might be worth. Arcutis B
Show less
Read more
Impact Snapshot
Event Time:
ARQT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARQT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARQT alerts
High impacting Arcutis Biotherapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
ARQT
News
- This Biotech Stock Could Cure Your Portfolio's Pain [Yahoo! Finance]Yahoo! Finance
- Arcutis Biotherapeutics (NASDAQ:ARQT) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ARQT&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall SMarketBeat
- Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar ChaudhuriGlobeNewswire
- Arcutis Biotherapeutics: Behind The Big Rally [Seeking Alpha]Seeking Alpha
- Arcutis Biotherapeutics (NASDAQ:ARQT) was given a new $37.00 price target on by analysts at Mizuho.MarketBeat
ARQT
Earnings
- 10/28/25 - Beat
ARQT
Sec Filings
- 12/8/25 - Form 4
- 12/8/25 - Form 3
- 12/8/25 - Form 8-K
- ARQT's page on the SEC website